Status:
COMPLETED
Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
Lead Sponsor:
HanAll BioPharma Co., Ltd.
Conditions:
Hypertension
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg in healthy male ...
Eligibility Criteria
Inclusion
- Healthy male, Age 20 to 45
- Subject must be willing and able to provide written informed consent to the study.
Exclusion
- History of any significant sickness, liver system, gall bladder system, kidney, nerve system, respiratory system, blood tumor, endocrine system, urinary system, mental disease, muscloskeletal system, immunity system, the ear, nose and throat system and cardiovascular system.
- History of any significant gastrointestinal system and surgery of gastrointestinal.
- History of any significant hypersensitivity to amlodipine, candesartan, aspirin, antibiotic.
- Over 10 tobaccos a day.
- Other condition which in the opinion of the investigator preclude endrollment into the study.
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01806311
Start Date
December 1 2012
End Date
August 1 2013
Last Update
April 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungnam national university hospital,clinical trial center
Daejeon, Chungcheongbul-do, South Korea, 301-721